| Document |
Document Title |
|
WO/2024/074501A1 |
The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.
|
|
WO/2024/062043A1 |
The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, R3, and R4 have the same meaning as that defined in the claims and the description. The present invention also relates to the use ...
|
|
WO/2024/035618A1 |
The invention relates to crystalline forms and processes for preparing a compound of Formula I (I) and pharmaceutically acceptable salts thereof which are useful for the treatment of bacterial infections, particularly mycobacterial infec...
|
|
WO/2024/031051A1 |
Provided herein are ionizable lipids, compositions comprising the ionizable lipids, and methods of making and using the same. The ionizable lipids provided herein can be formulated in lipid compositions for the delivery of macromolecules...
|
|
WO/2024/025881A2 |
Stimulator of Interferon Genes (STING) modulators and their use for treating a disease, disorder, or condition associated with STING.
|
|
WO/2024/018764A1 |
In the present invention, when converting the phenothiazine carbaldehyde derivative compound or phenothiazine acetyl derivative compound represented by general formula (b) (wherein, R1 is a monovalent aliphatic hydrocarbon group having 1...
|
|
WO/2024/011414A1 |
Disclosed in the present invention is a reaction method for secondary amine and o-diiodobenzene, comprising: reacting secondary amine with o-diiodobenzene in the presence of an alkali metal hydride or a Grignard reagent to complete the r...
|
|
WO/2024/012554A1 |
The present disclosure belongs to the field of biomedicine, and specifically relates to a method for preventing or treating neurodegenerative diseases or alleviating symptoms of neurodegenerative diseases. Said method comprises administe...
|
|
WO/2023/250002A1 |
The present disclosure is concerned with benzothiazone compounds that are capable of inhibiting Tau-SH3 signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders...
|
|
WO/2023/218203A1 |
The present invention relates to compounds that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical c...
|
|
WO/2023/216122A1 |
Disclosed are a singlet oxygen type photosensitizing material having aggregation-induced emission performance, and a preparation method and use therefor. The method comprises: using phenothiazine and an iodobenzene derivative as raw mate...
|
|
WO/2023/210623A1 |
The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
|
|
WO/2023/208170A1 |
Provided are a protease inhibitor, a method for preparing same, and use thereof. The protease inhibitor can be combined with one or more pharmaceutically acceptable excipients or one or more other active ingredients to be used as a PLpro...
|
|
WO/2023/202464A1 |
A purification method for an electron mediator on a biosensor. The electron mediator is provided with an amino group. The purification method comprises the following steps: weighing an electron mediator with a lower purity; reacting an a...
|
|
WO/2023/173889A1 |
The present application discloses an up-conversion long-afterglow chemiluminescence imaging nanoprobe, and a preparation method therefor and the use thereof. The fluorescence probe does not need to use rare earth elements, can receive a ...
|
|
WO/2023/173824A1 |
Disclosed in the present invention are a hydrophobic methylene blue fluorescent dye, and a preparation method therefor and the use thereof. The hydrophobic methylene blue fluorescent dye has a structural formula as shown in formula (I), ...
|
|
WO/2023/171473A1 |
The present invention provides a redox polymer or a redox mediator constituting the redox polymer, each of which is used for forming an electrochemical sensor capable of being suitably used for a measurement for a long period (a continuo...
|
|
WO/2023/164201A1 |
A compound which is useful as a STING inhibitor is provided. The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory a...
|
|
WO/2023/143350A1 |
Provided are a crystal form and salt of a phenothiazine compound, a preparation method therefor and a use thereof. A hydrochloride of the phenothiazine compound and a crystal thereof can be used as ferroptosis inhibitors, and the hydroch...
|
|
WO/2023/018472A9 |
N,N-disubstituted arylamine compounds and to their use as integrin agonists for enhancing binding of integrin-expressing cells to integrin-binding ligands or receptors.
|
|
WO/2023/132369A1 |
Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these. Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...
|
|
WO/2023/124728A1 |
The present invention relates to the technical field of organic synthesis. Disclosed are a method and system for preparing diphenylamine and phenothiazine from aniline. The method comprises: reacting an aniline raw material; carrying out...
|
|
WO/2023/115220A1 |
A combination comprising tilorone/nelfinavir; tilorone/molnupinavir; tilorone/remdesivir; tilorone/alfacalcidol; tilorone/clofazimine; tilorone/danazol; tilorone/manidipine; tilorone/sertraline; tilorone/trifluoperazine; remdesivir/hexac...
|
|
WO/2023/111869A1 |
A method for synthesizing a compound comprising forming a liquid mixture by adding a CH-acid, 2-Mercaptobenzimidazole, and a benzaldehyde component to an ionic liquid of trihexyltetradecylphosphonium bromide. The method may further compr...
|
|
WO/2023/100982A1 |
An acrylic elastomer copolymer constituted by containing a copolymerizable anti-aging agent represented by general formula (I) (R1: C1-20 aliphatic hydrocarbon group, C7-20 aralkyl group, or C2-20 acyl group, R2: hydrogen atom or methyl ...
|
|
WO/2023/098740A1 |
The present invention belongs to the technical field of photoelectric materials, and particularly relates to an organic room-temperature electrophosphorescent material, and a preparation method therefor and an organic electroluminescent ...
|
|
WO/2023/065182A1 |
Disclosed are a benzothiazinone derivative based on an alkynyl linking arm, a preparation method therefor, and a use thereof. The present invention is an inventive improvement on the position of a side chain connected to the skeleton of ...
|
|
WO/2023/054393A1 |
A compound represented by the following general formula (1), a hole-transporting material including the compound, a hole-transporting material composition for a photoelectric conversion element including the hole-transporting material, a...
|
|
WO/2023/043432A1 |
The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 has any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds...
|
|
WO/2023/021832A1 |
Provided is a crosslinkable acrylic rubber composition containing: (A) an acrylic rubber containing a carbamate group and a carboxyl group; (B) a phenothiazine-based antioxidant represented by general formula [I] [where R3 represents a h...
|
|
WO/2023/285787A1 |
A process for preparing a compound of formula I, or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula I.
|
|
WO/2023/279205A1 |
The present technology relates to UV radiation-absorbing and/or visible radiation-absorbing compounds, and use of same in the preparation of compositions for protecting biological and nonbiological material against UV and/or visible radi...
|
|
WO/2023/274396A1 |
A class of benzazepine heterocyclic compounds that can be used as RORγt agonists and an application thereof in medicine, as well as a pharmaceutical composition comprising this class of compound and an application thereof in medicine. S...
|
|
WO/2022/243549A1 |
The present invention relates to compounds capable of modulating the activity of the cellular prion protein (PrPC) and their use for the treatment of immune and neurodegenerative diseases.
|
|
WO/2022/222856A1 |
A benzo-condensed ring compound of formula (I), a pharmaceutical composition comprising same, a preparation method therefor and a use thereof as an HDAC6 inhibitor.
|
|
WO/2022/204902A1 |
A benzothiazinone derivative substituted with trifluoromethyl at 6-position, and a preparation method therefor and the use thereof. A series of compounds are obtained by means of changing the benzene ring of the benzothiazinone backbone,...
|
|
WO/2022/181621A1 |
A condensed heterocyclic compound–containing composition comprising: a compound represented by general formula (A); and at least one compound selected from the group consisting of specific condensed heterocyclic compounds, specific aro...
|
|
WO/2022/162471A1 |
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
|
|
WO/2022/153962A1 |
The problem to be solved by the present invention is to provide: a compound useful as a hole transport material for photoelectric conversion elements whereby electric current can be efficiently taken out; and a photoelectric conversion e...
|
|
WO/2022/126819A1 |
Disclosed are a photoactivated novel organic small-molecular matrix, a preparation method therefor and the use thereof in MALDI mass spectrometry detection. Compounds with structures as shown in formula I, formula II and formula III are ...
|
|
WO/2022/109329A1 |
Redox active polycyclic compounds and related electrode material, electrode chemical cell battery, methods and systems are described. In particular, tricyclic compounds having a redox potential of 0.20 V to 2.0 V with reference to Zn/Zn2...
|
|
WO/2022/104070A2 |
Disclosed are phenothiazine compounds which reduce Abeta toxicity in vivo, reduce microglial inflammation as indicated by secretion of TNF-alpha, reduce intracerebral hemorrhage in vivo toxicity as indicated by preserved motor and cognit...
|
|
WO/2022/076628A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...
|
|
WO/2022/076629A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions, containing at least one such modulator, methods of treatment of cystic fibrosis usi...
|
|
WO/2022/069001A1 |
The invention relates to a compound, to a rubber blend containing said compound, a vehicle tire comprising the rubber blend in at least one component, a process for preparing the compound and the use of the compound as ageing protectant ...
|
|
WO/2022/058965A1 |
Provided herein, inter alia, are compounds of fatty acid glycerol derivatives and compositions including the same.
|
|
WO/2022/049604A1 |
The present invention relates to processes and intermediates for the synthesis of Revefenacin or pharmaceutically acceptable salts thereof.
|
|
WO/2022/049872A1 |
A phenothiazine derivative represented by the general formula (where, R1 is a C1-20 monovalent aliphatic hydrocarbon group or a C7-20 aralkyl group, R2∙Ar is an aralkyl group, R2 thereof is a C1-10 divalent aliphatic hydrocarbon group,...
|
|
WO/2022/043491A2 |
Disclosed herein are detectable moieties and detectable conjugates comprising one or more detectable moieties. In some embodiments, the disclosed detectable moieties have a narrow wavelength and are suitable for multiplexing. Also disclo...
|
|
WO/2022/022612A1 |
The invention relates to novel glutamine analogs shown as the formula I, a composition containing the glutamine analogs and the use thereof.
|
